Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 7,007 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Not listed Phase 3 Interventional

Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms

NCT00094874
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Acupuncture
Procedure
Lead sponsor
The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 2:38 PM EDT
Not yet recruiting Early Phase 1 Interventional

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

NCT07643974
View directory record Official record
Conditions
Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions
Gentamicin, Lactobacillus Rhamnosus GG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients

NCT04266860
View directory record Official record
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
Experimental - Test Results and Education
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

NCT06318676
View directory record Official record
Conditions
Renal Impairment
Interventions
Mezigdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 82 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Not listed No phase listed Observational

Care Transitions in Renal Disease Patients

NCT01842776
View directory record Official record
Conditions
Renal Disease
Interventions
Not listed
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 4 Interventional

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

NCT00073710
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Biobehavioral Effects of Emotional Expression in Cancer

NCT00505310
View directory record Official record
Conditions
Kidney Cancer
Interventions
Writing, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 15, 2026, 2:38 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
BION-1301, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma

NCT00113217
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

NCT01182168
View directory record Official record
Conditions
Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
Interventions
gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glasdegib Renal Impairment Study

NCT03596567
View directory record Official record
Conditions
Renal Impairment
Interventions
Glasdegib single 100 mg dose in normal healthy subjects, Glasdegib single 100 mg dose in moderate renal impairment subjects, Glasdegib single 100 mg dose in severe renal impairment subjects
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 15, 2026, 2:38 PM EDT
Active, not recruiting Not applicable Interventional

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology

NCT05592665
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Survey Questionnaire
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

NCT05740007
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
IW-3300 rectal foam, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

NCT05155033
View directory record Official record
Conditions
Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
Interventions
Pembrolizumab, Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed No phase listed Observational

AMPED Outcomes Registry of Post-ED Pain Management

NCT01626235
View directory record Official record
Conditions
Soft Tissue Injuries, Gouty Arthritis, Fractures, Ureteral Colic, Dysmenorrhea
Interventions
Not listed
Lead sponsor
Radnor Registry Research, Inc
Industry
Eligibility
18 Years and older
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 15, 2026, 2:38 PM EDT
Completed No phase listed Observational

Systolic Pressure Intervention Trial Factors Affecting Factors Affecting Atherosclerosis Study

NCT01475747
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
12
States / cities
Palo Alto, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 15, 2026, 2:38 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

NCT02138838
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 15, 2026, 2:38 PM EDT
Active, not recruiting Not applicable Interventional

How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding

NCT07125326
View directory record Official record
Conditions
Urinary Retention, Urinary Tract Infection (Diagnosis), Postpartum Acute Urinary Retention, Postpartum Care, Voiding Dysfunction
Interventions
Intermittent catheterization, Continuous catheterization
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Active, not recruiting Phase 2 Interventional

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

NCT02171104
View directory record Official record
Conditions
Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

NCT05710848
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
STM-416
Drug
Lead sponsor
SURGE Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Mesa, Arizona • Tucson, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria

NCT03663855
View directory record Official record
Conditions
Cystinuria
Interventions
Tiopronin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 15, 2026, 2:38 PM EDT
Terminated Phase 3 Interventional

Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer

NCT00126178
View directory record Official record
Conditions
Kidney Cancer, Renal Cell Carcinoma
Interventions
HSPPC-96
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
San Francisco, California • Stanford, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 15, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

NCT05141006
View directory record Official record
Conditions
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interventions
BOTOX, Placebo for BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Homewood, Alabama • Mobile, Alabama • Buena Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 15, 2026, 2:38 PM EDT
Terminated Phase 1 Interventional

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

NCT02947152
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Renal Cell Carcinoma
Interventions
HKT288
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 15, 2026, 2:38 PM EDT